A prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has once again been named a constituent of the FTSE4Good Index Series. This recognition, marking the fourth year in a row, highlights the company’s exceptional performance in sustainability.
The FTSE4Good Index Series, established in 2001 by FTSE Russell, a subsidiary of the London Stock Exchange Group, aims to track the performance of companies that excel in sustainability practices. Companies included in the index are selected based on an independent assessment of data from over 8,000 companies across 47 developed and emerging markets. WuXi Biologics has notably improved its FTSE Russell ESG score over the years, with its 2024 score placing it in the top 7% of its industry.
Dr. Chris Chen, CEO and Chairman of the ESG Committee at WuXi Biologics, expressed pride in the company’s continued inclusion in the FTSE4Good Index Series. “Being recognized by FTSE Russell once again underscores our strong commitment to sustainability,” said Dr. Chen. “This achievement reflects the success of our comprehensive ESG strategy and effective implementation. We remain dedicated to making sustainability a cornerstone of our growth, ensuring positive contributions to the global community.”
Aligned with the United Nations Sustainable Development Goals, WuXi Biologics has made significant strides in sustainable development, earning recognition from major ESG rating agencies. Recently, the company was added to the S&P Dow Jones Sustainability™ World Index and Emerging Markets Index, received a “AAA” rating from MSCI ESG Ratings, achieved the Platinum Medal from EcoVadis, and was recognized by Sustainalytics as an Industry and Regional Top-Rated Company. Additionally, WuXi Biologics was named to the CDP Water Security “A List” and awarded an “A-” CDP Climate Change score.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global CRDMO providing end-to-end solutions for the discovery, development, and manufacturing of biologics—from concept to commercialization—for the benefit of patients worldwide.
With a workforce of over 12,000 across China, the United States, Ireland, Germany, and Singapore, WuXi Biologics leverages advanced technologies and expertise to deliver efficient and cost-effective biologics solutions. As of December 31, 2023, the company is supporting 698 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics is committed to Environmental, Social, and Governance (ESG) responsibilities, viewing them as central to its ethos and business strategy. The company utilizes cutting-edge biomanufacturing technologies and clean energy sources and has established an ESG committee led by its CEO to guide its comprehensive ESG strategy and implementation.
